[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Hospitalier de Bligny\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":38},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":20,"conditions":21,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100632275",false,"NCT07511569","Prospective Exploratory Study of a Multiomic Blood Biomarker Panel to Predict Chemotherapy-Induced Peripheral Neuropathy (CIPN)","PRECISE1","Inclusion Criteria:\n\n* Patients who have received detailed information about the study and have signed, with the investigator, a consent form to participate in the study\n* Patients being treated for cancer at any stage of the disease and scheduled to receive chemotherapy including one (and only one) of the following molecules: paclitaxel, docetaxel, or oxaliplatin, for a planned duration of 9 weeks or more\n* Age \\> 18 years\n* Life expectancy \\> 3 months\n* Patient affiliated with or entitled to social security\n\nExclusion Criteria:\n\n* Patients already suffering from neuropathy or chronic neurogenic pain\n* Patients with type 1 or type 2 diabetes (for more than 10 years for type 2 diabetes)\n* Patients who have already received neurotoxic cancer treatment including those in clinical trials\n* Patients receiving two of the study molecules simultaneously (only one study molecule is permitted, including in combination chemotherapy but that does not include another neurotoxic molecule)\n* Patients receiving immunotherapy","ALL",{"count":17,"type":18},192,"ESTIMATED","OBSERVATIONAL","The goal of this prospective, multicenter, observational cohort study with longitudinal blood sampling and standardized neurological evaluation over 6 months is to identify biomarkers to predict the overall occurrence of chronic chemotherapy-induced peripheral neuropathy (CIPN, any grade), in each of two treatment subgroups (taxanes and oxaliplatin). It involves integration of clinical data and plasma multiomic biomarkers (proteomic + metabolomic panel) analyzed via supervised machine learning to identify predictive features of CIPN.",[22,23,24,25],"Chemotherapy Induced Neuropathic Pain","Neuropathy Toxic","Taxane-induced Peripheral Neuropathy","Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients","NOT_YET_RECRUITING","2026-04-07",{"date":29,"type":30},"2026-04-13","ACTUAL",{"date":32,"type":18},"2027-01-04",{"date":34,"type":18},"2029-06-04",{"name":36,"class":37},"Centre Hospitalier de Bligny","OTHER",""]